News
-
BiondVax Pharmaceuticals announced that 6 days post infection, hamsters treated with the company’s NanoAb inhaled nanosized antibodies had levels of SARS-COV-2 in their lungs reduced to levels 30 times lower than hamsters that got an… Read more . . .
-
Inhaled antiviral developer Pneumagen has announced the appointment of Adaptimmune Therapeutics founder James Noble as non-executive Chairman of the company’s board of directors. Noble also co-founded Immunocore and serves as Chairman of Sutura Therapeutics, Celleron,… Read more . . .
-
Pulmatrix has announced that a Phase 1 PK trial of its PUR3100 dihydroergotamine (DHE) DPI in healthy volunteers demonstrated that all 3 doses tested produced peak exposures in the desired range with a Tmax of… Read more . . .
-
Copley Scientific has announced the appointments of Jamie Clayton as Managing Director and Matthew Fenn as Head of Business Development. Clayton joined powder characterization specialist Freeman Technology in 2008 and then served as Freeman’s Operations… Read more . . .
-
Cipla has announced a €15 million equity investment in inhaled mRNA developer Ethris. In February 2022, Ethris announced that it had closed a $26.3 million Series B financing round with proceeds going to support its… Read more . . .
-
According to Polarean Imaging, the FDA has approved the company’s NDA for its Xenoview inhaled xenon-129 gas blend, a hyperpolarized contrast agent for MRI imaging of lung ventilation. Xenoview is approved for use in patients… Read more . . .
-
According to Harm Reduction Therapeutics, the FDA has accepted the company’s NDA for its RiVive naloxone nasal spray for the reversal of opioid overdose and granted the NDA Priority Review designation. Harm Reduction had announced the… Read more . . .
-
According to the Centenary Institute, the New South Wales COVID-19 Vaccine Acceleration Research Grants Program has awarded a grant worth AU$995,867 to researchers at the Centenary Institute and the University of Sydney to support development… Read more . . .
-
Armata Pharmaceuticals announced that it has completed the Phase 1b/2a SWARM-P.a. trial of its AP-PA02 inhaled phage cocktail in cystic fibrosis patients who have chronic P. aeruginosa lung infections. The SWARM-P.a. study was initiated in 2020 with support… Read more . . .
-
Oragenics said that results from a toxicology study of its NT-CoV2-1 intranasal vaccine conducted in rabbits “confirm a safety and immunogenicity profile that further support its plan to submit regulatory filings required to progress to… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany